You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTrastuzumab
Accession NumberDB00072  (BIOD00098, BTD00098)
TypeBiotech
GroupsApproved, Investigational
Description

A recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein. Produced in CHO cell culture.*

Protein structureDb00072
Protein chemical formulaC6470H10012N1726O2013S42
Protein average weight145531.5000
Sequences
>Anti-HER2 Light chain 1
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPS
RFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
>Anti-HER2 Heavy chain 1
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRY
ADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPPKSCDKTHTCPPCPAPELLG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD
ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
>Anti-HER2 Light chain 2
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPS
RFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
>Anti-HER2 Heavy chain 2
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRY
ADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPPKSCDKTHTCPPCPAPELLG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD
ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
>1n8z_A|Herceptin|||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23443.1|MW 23443.1|
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPS
RFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
>1n8z_B|Herceptin|||VH-CH1 (VH(1-120)+CH1(121-218))|||||||220||||MW 23404.2|MW 23404.2|
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRY
ADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
>7637_H|trastuzumab|||H-GAMMA-1 (VH(1-120)+CH1(121-218)+HINGE-REGION(219-233)+CH2(234-343)+CH3(344-450))|||||||450||||MW 49236.5|MW 49236.5|
EPKSCDKTHTCPPCP
>7637_L|trastuzumab|||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23443.1|MW 23443.1|
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPS
RFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Download FASTA Format
Synonyms
SynonymLanguageCode
Anti HER2Not AvailableNot Available
Ig gamma-1 chain C regionNot AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
HerceptinkitGenentech, Inc.1998-09-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Herceptinpowder for solution440 mgintravenousHoffmann La Roche LimitedNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
CAS number180288-69-1
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
Pharmacology
IndicationFor treatment of early stage HER2-positive breast cancer, or metastatic breast cancer that substantially overexpress HER2.
PharmacodynamicsUsed in the treatment of HER2-positive breast cancer. HER2 protein overexpression is observed in 25%-30% of primary breast cancers.Trastuzumab has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumorcells that overexpress HER2. It is a mediator of antibody dependent cellular cytotoxicity, in that the binding of the antibody to HER2 overexpressing cells leads to preferential cell death.
Mechanism of actionTrastuzumab binds to the HER2 (or c-erbB2) proto-oncogene, an EGF receptor-like protein found on 20-30% of breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells.
AbsorptionPeak and trough plasma concentrations at steady state (between weeks 16 and 32) approximately 123 and 79 mcg/mL, respectively.
Volume of distribution
  • 44 mL/kg
Protein bindingNot Available
Metabolism

Most likely removed by opsonization via the reticuloendothelial system.

Route of eliminationNot Available
Half lifeaverage 28.5 days. Pharmacokinetics are nonlinear; increased doses are associated with increased mean half-life and decreased clearance.
Clearance

Elimination may involve clearance of IgG through the reticuloendothelial system.

ToxicityAdministration of trastuzumab can result in ventricular dysfunction and congestive heart failure. Risk of cardiotocity is especially elevated in patients recieving concurrent anthracycline or cyclophosphamide therapy.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Trastuzumab Action PathwayDrug actionSMP00476
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Fibroblast growth factor receptor 4
Gene symbol: FGFR4
UniProt: P22455
rs351855 Not AvailableC AlleleReduced response to herceptin16822847
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Receptor tyrosine-protein kinase erbB-2
Gene symbol: ERBB2
UniProt: P04626
rs1801200 Not AvailableG Allele, heterozygoteCardiotoxicity17693647
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Kit
Powder for solutionintravenous440 mg
Prices
Unit descriptionCostUnit
Herceptin 440 mg Solution Vial3581.2USD vial
Herceptin 440 mg vial3443.46USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
Canada21030592005-03-222012-06-15
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point61 °C (FAB fragment), 71 °C (whole mAb)Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)
hydrophobicity-0.415Not Available
isoelectric point8.45Not Available
References
Synthesis ReferenceNot Available
General Reference
  1. Bange J, Zwick E, Ullrich A: Molecular targets for breast cancer therapy and prevention. Nat Med. 2001 May;7(5):548-52. Pubmed
  2. Menard S, Pupa SM, Campiglio M, Tagliabue E: Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003 Sep 29;22(42):6570-8. Pubmed
  3. Kute T, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, Mitchell T, Vaughn JP: Development of Herceptin resistance in breast cancer cells. Cytometry A. 2004 Feb;57(2):86-93. Pubmed
  4. Albanell J, Codony J, Rovira A, Mellado B, Gascon P: Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol. 2003;532:253-68. Pubmed
  5. Tan AR, Swain SM: Ongoing adjuvant trials with trastuzumab in breast cancer. Semin Oncol. 2003 Oct;30(5 Suppl 16):54-64. Pubmed
  6. IGMT Link
  7. IGMT Link
  8. Nebija D, Kopelent-Frank H, Urban E, Noe CR, Lachmann B: Comparison of two-dimensional gel electrophoresis patterns and MALDI-TOF MS analysis of therapeutic recombinant monoclonal antibodies trastuzumab and rituximab. J Pharm Biomed Anal. 2011 Dec 5;56(4):684-91. doi: 10.1016/j.jpba.2011.07.006. Epub 2011 Jul 18. Pubmed
    #American Society of Health System Pharmacists, Inc., DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995.Trastuzumab; [updated 2014 Nov 05; cited 2014 Nov 12.Available fromhttp://web.b.ebscohost.com/dynamed/detail?vid=2&sid=c9ea9657-342a-4b9b-a3bb-bf363d5d58c4%40sessionmgr112&hid=110&bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#db=dme&AN=233586
External Links
ATC CodesL01XC03
AHFS CodesNot Available
PDB Entries
FDA labelDownload (41 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbataceptMay enhance the neutropenic effect of Immunosuppressants.
AdalimumabMay enhance the neutropenic effect of Immunosuppressants.
ado-trastuzumab emtansineMay enhance the neutropenic effect of Immunosuppressants.
AlemtuzumabMay enhance the neutropenic effect of Immunosuppressants.
AltretamineMay enhance the neutropenic effect of Immunosuppressants.
AmsacrineMay enhance the neutropenic effect of Immunosuppressants.
AnakinraMay enhance the neutropenic effect of Immunosuppressants.
Antithymocyte globulinMay enhance the neutropenic effect of Immunosuppressants.
AzacitidineMay enhance the neutropenic effect of Immunosuppressants.
AzathioprineMay enhance the neutropenic effect of Immunosuppressants.
BasiliximabMay enhance the neutropenic effect of Immunosuppressants.
BelataceptMay enhance the neutropenic effect of Immunosuppressants.
BelimumabMonoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.
BleomycinMay enhance the neutropenic effect of Immunosuppressants.
Brentuximab vedotinMay enhance the neutropenic effect of Immunosuppressants.
BusulfanMay enhance the neutropenic effect of Immunosuppressants.
CabazitaxelMay enhance the neutropenic effect of Immunosuppressants.
CanakinumabMay enhance the neutropenic effect of Immunosuppressants.
CapecitabineMay enhance the neutropenic effect of Immunosuppressants.
CarboplatinMay enhance the neutropenic effect of Immunosuppressants.
CarmustineMay enhance the neutropenic effect of Immunosuppressants.
Certolizumab pegolMay enhance the neutropenic effect of Immunosuppressants.
ChlorambucilMay enhance the neutropenic effect of Immunosuppressants.
CisplatinMay enhance the neutropenic effect of Immunosuppressants.
CladribineMay enhance the neutropenic effect of Immunosuppressants.
CorticotropinMay enhance the neutropenic effect of Immunosuppressants.
Cortisone acetateMay enhance the neutropenic effect of Immunosuppressants.
CyclophosphamideMay enhance the neutropenic effect of Immunosuppressants.
CytarabineMay enhance the neutropenic effect of Immunosuppressants.
DacarbazineMay enhance the neutropenic effect of Immunosuppressants.
DactinomycinMay enhance the neutropenic effect of Immunosuppressants.
DasatinibMay enhance the neutropenic effect of Immunosuppressants.
DaunorubicinMay enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic).
DocetaxelMay enhance the neutropenic effect of Immunosuppressants.
EculizumabMay enhance the neutropenic effect of Immunosuppressants.
EpirubicinMay enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic).
EstramustineMay enhance the neutropenic effect of Immunosuppressants.
EtanerceptMay enhance the neutropenic effect of Immunosuppressants.
EtoposideMay enhance the neutropenic effect of Immunosuppressants.
EverolimusMay enhance the neutropenic effect of Immunosuppressants.
FingolimodMay enhance the neutropenic effect of Immunosuppressants.
FloxuridineMay enhance the neutropenic effect of Immunosuppressants.
FludarabineMay enhance the neutropenic effect of Immunosuppressants.
FludrocortisoneMay enhance the neutropenic effect of Immunosuppressants.
Fluticasone furoateMay enhance the neutropenic effect of Immunosuppressants.
GemcitabineMay enhance the neutropenic effect of Immunosuppressants.
Gemtuzumab ozogamicinMay enhance the neutropenic effect of Immunosuppressants.
Glatiramer AcetateMay enhance the neutropenic effect of Immunosuppressants.
golimumabMay enhance the neutropenic effect of Immunosuppressants.
HomoharringtonineMay enhance the neutropenic effect of Immunosuppressants.
HydroxyureaMay enhance the neutropenic effect of Immunosuppressants.
IbritumomabMay enhance the neutropenic effect of Immunosuppressants.
IdarubicinMay enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic).
IfosfamideMay enhance the neutropenic effect of Immunosuppressants.
ImiquimodMay enhance the neutropenic effect of Immunosuppressants.
InfliximabMay enhance the neutropenic effect of Immunosuppressants.
IrinotecanMay enhance the neutropenic effect of Immunosuppressants.
L-PhenylalanineMay enhance the neutropenic effect of Immunosuppressants.
LeflunomideMay enhance the neutropenic effect of Immunosuppressants.
LenalidomideMay enhance the neutropenic effect of Immunosuppressants.
LomustineMay enhance the neutropenic effect of Immunosuppressants.
MelphalanMay enhance the neutropenic effect of Immunosuppressants.
MercaptopurineMay enhance the neutropenic effect of Immunosuppressants.
MethotrexateMay enhance the neutropenic effect of Immunosuppressants.
MethylprednisoloneMay enhance the neutropenic effect of Immunosuppressants.
MitoxantroneMay enhance the neutropenic effect of Immunosuppressants.
Mycophenolate mofetilMay enhance the neutropenic effect of Immunosuppressants.
Mycophenolic acidMay enhance the neutropenic effect of Immunosuppressants.
NatalizumabMay enhance the neutropenic effect of Immunosuppressants.
NelarabineMay enhance the neutropenic effect of Immunosuppressants.
NilotinibMay enhance the neutropenic effect of Immunosuppressants.
ObinutuzumabMay enhance the neutropenic effect of Immunosuppressants.
OxaliplatinMay enhance the neutropenic effect of Immunosuppressants.
PanobinostatMay enhance the neutropenic effect of Immunosuppressants.
PazopanibMay enhance the neutropenic effect of Immunosuppressants.
PegaspargaseMay enhance the neutropenic effect of Immunosuppressants.
PemetrexedMay enhance the neutropenic effect of Immunosuppressants.
PentostatinMay enhance the neutropenic effect of Immunosuppressants.
PomalidomideMay enhance the neutropenic effect of Immunosuppressants.
PralatrexateMay enhance the neutropenic effect of Immunosuppressants.
PrednisoneMay enhance the neutropenic effect of Immunosuppressants.
ProcarbazineMay enhance the neutropenic effect of Immunosuppressants.
RilonaceptMay enhance the neutropenic effect of Immunosuppressants.
RituximabMay enhance the neutropenic effect of Immunosuppressants.
RuxolitinibMay enhance the neutropenic effect of Immunosuppressants.
SecukinumabMay enhance the neutropenic effect of Immunosuppressants.
SiltuximabMay enhance the neutropenic effect of Immunosuppressants.
SirolimusMay enhance the neutropenic effect of Immunosuppressants.
SorafenibMay enhance the neutropenic effect of Immunosuppressants.
StreptozocinMay enhance the neutropenic effect of Immunosuppressants.
SunitinibMay enhance the neutropenic effect of Immunosuppressants.
TemozolomideMay enhance the neutropenic effect of Immunosuppressants.
TemsirolimusMay enhance the neutropenic effect of Immunosuppressants.
TeniposideMay enhance the neutropenic effect of Immunosuppressants.
TeriflunomideMay enhance the neutropenic effect of Immunosuppressants.
ThalidomideMay enhance the neutropenic effect of Immunosuppressants.
ThiotepaMay enhance the neutropenic effect of Immunosuppressants.
TioguanineMay enhance the neutropenic effect of Immunosuppressants.
TocilizumabMay enhance the neutropenic effect of Immunosuppressants.
TofacitinibMay enhance the neutropenic effect of Immunosuppressants.
TopotecanMay enhance the neutropenic effect of Immunosuppressants.
TositumomabMay enhance the neutropenic effect of Immunosuppressants.
TrabectedinMay enhance the neutropenic effect of Immunosuppressants.
TretinoinMay enhance the neutropenic effect of Immunosuppressants.
VedolizumabMay enhance the neutropenic effect of Immunosuppressants.
VinblastineMay enhance the neutropenic effect of Immunosuppressants.
VincristineMay enhance the neutropenic effect of Immunosuppressants.
VinorelbineMay enhance the neutropenic effect of Immunosuppressants.
Food InteractionsNot Available

Targets

1. Receptor tyrosine-protein kinase erbB-2

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antibody

Components

Name UniProt ID Details
Receptor tyrosine-protein kinase erbB-2 P04626 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  2. Leveque D, Gigou L, Bergerat JP: Clinical pharmacology of trastuzumab. Curr Clin Pharmacol. 2008 Jan;3(1):51-5. Pubmed
  3. Lin A, Rugo HS: The role of trastuzumab in early stage breast cancer: current data and treatment recommendations. Curr Treat Options Oncol. 2007 Feb;8(1):47-60. Pubmed
  4. Treish I, Schwartz R, Lindley C: Pharmacology and therapeutic use of trastuzumab in breast cancer. Am J Health Syst Pharm. 2000 Nov 15;57(22):2063-76; quiz 2077-9. Pubmed

2. Epidermal growth factor receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Epidermal growth factor receptor P00533 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

3. Complement C1r subcomponent

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Complement C1r subcomponent P00736 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

4. Complement C1q subcomponent subunit A

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Complement C1q subcomponent subunit A P02745 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

5. Complement C1q subcomponent subunit B

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Complement C1q subcomponent subunit B P02746 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

6. Complement C1q subcomponent subunit C

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Complement C1q subcomponent subunit C P02747 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

7. Complement C1s subcomponent

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Complement C1s subcomponent P09871 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

8. High affinity immunoglobulin gamma Fc receptor I

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
High affinity immunoglobulin gamma Fc receptor I P12314 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Curnow RT: Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):210-5. Pubmed

9. Low affinity immunoglobulin gamma Fc region receptor II-a

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Low affinity immunoglobulin gamma Fc region receptor II-a P12318 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8. Pubmed

10. Low affinity immunoglobulin gamma Fc region receptor II-b

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Low affinity immunoglobulin gamma Fc region receptor II-b P31994 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

11. Low affinity immunoglobulin gamma Fc region receptor II-c

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Low affinity immunoglobulin gamma Fc region receptor II-c P31995 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

12. Low affinity immunoglobulin gamma Fc region receptor III-B

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Low affinity immunoglobulin gamma Fc region receptor III-B O75015 Details

References:

  1. Bowles JA, Weiner GJ: CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods. 2005 Sep;304(1-2):88-99. Pubmed
  2. Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM: Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem. 2004 Dec 24;279(52):53907-14. Epub 2004 Oct 7. Pubmed
  3. Kubo M, Morisaki T, Kuroki H, Tasaki A, Yamanaka N, Matsumoto K, Nakamura K, Onishi H, Baba E, Katano M: Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer. Anticancer Res. 2003 Nov-Dec;23(6a):4443-9. Pubmed
  4. Yamaguchi Y, Hironaka K, Okawaki M, Okita R, Matsuura K, Ohshita A, Toge T: HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab. Anticancer Res. 2005 Mar-Apr;25(2A):827-32. Pubmed
  5. Xie Z, Guo N, Yu M, Hu M, Shen B: A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis. J Immunol Methods. 2005 Jan;296(1-2):95-101. Epub 2004 Nov 19. Pubmed

13. Low affinity immunoglobulin gamma Fc region receptor III-A

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Low affinity immunoglobulin gamma Fc region receptor III-A P08637 Details

References:

  1. Suzuki E, Niwa R, Saji S, Muta M, Hirose M, Iida S, Shiotsu Y, Satoh M, Shitara K, Kondo M, Toi M: A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clin Cancer Res. 2007 Mar 15;13(6):1875-82. Pubmed

Enzymes

1. Cytochrome P450 19A1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 19A1 P11511 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on June 24, 2015 16:22